Bone mineral density in patients with Crohn's disease during long‐term treatment with azathioprine
| Autor: | Claes-Henrik Florén, Jacek Bartosik, Bo Ahrén, M Bengtsson, Karl Obrant |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.drug_class medicine.medical_treatment Azathioprine Gastroenterology Absorptiometry Photon Crohn Disease Bone Density Internal medicine Internal Medicine medicine Humans Aged Retrospective Studies Bone mineral Chemotherapy Crohn's disease business.industry Retrospective cohort study Ileitis Middle Aged Colitis medicine.disease Surgery Toxicity Prednisolone Corticosteroid Female business Immunosuppressive Agents medicine.drug |
| Zdroj: | Journal of Internal Medicine. 243:123-126 |
| ISSN: | 1365-2796 0954-6820 |
| DOI: | 10.1046/j.1365-2796.1998.00246.x |
| Popis: | OBJECTIVES: To ascertain whether patients with Crohn's disease treated with azathioprine maintained bone mineral mass better than patients treated with steroids alone. DESIGN: Retrospective study. SETTING: University Hospital of Malmo, Sweden. SUBJECTS: A total of 59 patients with ileocolonic, ileocaecal or colonic Crohn's disease. METHODS: Bone mass was assessed by dual photon X-ray absorptiometry at the level of L2-L4. RESULTS: Patients treated with a high lifetime dose of steroids (> 5 g prednisolone) had significantly (P = 0.011) lower Z-score of L2-L4 (-0.87 +/- 1.11; 11 SD) than steroid-treated patients, who had received a low dose of prednisolone (< 5 g) (0.08 +/- 1.16 SD). Azathioprine did not negatively influence the steroid effect on bone mineral density. CONCLUSIONS: Azathioprine does not seem to affect bone mineral density by itself. However, by being steroid-saving, it seems to conserve bone mineral mass in patients with Crohn's disease. (Less) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text